As previously reported, Oppenheimer downgraded RxSight (RXST) to Perform from Outperform and removed the firm’s $28 price target Oppenheimer notes that the company’s pre-announced Q2 sales of $33.6M missed its/Street’s $39.6M/$39.8M forecast, driven by significantly lower than expected LDD placements. Utilization of already installed LDDs also slightly trailed Oppenheimer’s thinking, and 2025 sales guidance was cut to $120M-$130M from $160M-$175M, implying further reduced utilization in the second half of the year. The firm believes there is additional conservatism in the updated guidance and the shares post-market suggest a depressed 1-time EV/sales multiple. However, visibility has now been meaningfully reduced, particularly with new system demand well below expectations and as RxSight’s new initiatives don’t seem to be quick fixes, Oppenheimer adds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight price target lowered to $9 from $18 at BofA
- RxSight downgraded to Perform from Outperform at Oppenheimer
- RxSight price target lowered to $9 from $17 at Stifel
- RxSight downgraded to Neutral from Buy at BTIG
- RxSight’s Strategic Initiatives and International Expansion Support Buy Rating Amidst Revenue Challenges